Antigenotoxic effects of rutin against methotrexate genotoxicity in Swiss albino mice
Ch Ashoka1, Mustak Mohammed. S.2,*
1Department of Zoology, Government Science College, Nrupathunga Road, Bangalore-560 001, Karnataka, India
2Departments of Applied Zoology, Mangalore University, Mangalagangothri-574 199, Mangalore, Karnataka, India
*For Correspondence Address: firstname.lastname@example.org, email@example.com
Online published on 30 December, 2019.
Cancer chemoprevention with natural phytochemical compounds is an emerging strategy to prevent, impede, delay, or cure cancer. The aim of the study is to evaluate the anticlastogenic potency of the rutin, a flavonoid to modulate the side effects induced by the anticancer drug Methotrexate. Methotrexate is an antimetabolite drug broadly used in the treatment of cancer and autoimmune diseases which causes an array of many side effects. Different doses of rutin (50, 100 and 150 mg/kg bw) were given once daily for five days orally and methotrexate (20mg/kgbw) was administered on the fourth day intraperitoneally. To understand the protective effect of rutin against methotrexate side effects, micronucleus test and chromosome aberration tests were performed at 48h post methotrexate administration. The results showed that 20mg/kgbw of MTX significantly induced MN in polychromatic erythrocytes (p<0.05) and resulted in significant increase in total chromosomal aberrations (41.8±3.70%; p<0.05). Further, pre-treatment with the flavonoid rutin reduced the MNPCE and chromosomal aberrations in bone marrow and MN NCE in peripheral blood in comparison to MTX group. The Rutin supported the recovery from the mitotic suppression compared to MTX treated mice. Thus, the present study implies the major therapeutic use of rutin against genotoxic effects of methotrexate.
Methotrexate, Rutin, Micronucleus, Mitotic Index, Polychromatic Erythrocytes, Chromosomal aberrations.